Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferoxamine
Drug ID BADD_D00596
Description Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indications and Usage Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Marketing Status approved; investigational
ATC Code V03AC01
DrugBank ID DB00746
KEGG ID D03670
MeSH ID D003676
PubChem ID 2973
TTD Drug ID D0FJ8A
NDC Product Code Not Available
UNII J06Y7MXW4D
Synonyms Deferoxamine | Desferrioxamine | Desferioximine | Deferoxamine B | Desferrioxamine B | Deferoximine | Deferrioxamine B | Desferroxamine | Desferrioxamine B Mesylate | Mesylate, Desferrioxamine B | Deferoxamine Mesilate | Mesilate, Deferoxamine | Deferoxamine Mesylate | Mesylate, Deferoxamine | Deferoxamine Methanesulfonate | Methanesulfonate, Deferoxamine | Desferal
Chemical Information
Molecular Formula C25H48N6O8
CAS Registry Number 70-51-9
SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemochromatosis12.02.08.002; 09.01.10.005; 14.13.03.0010.002726%Not Available
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatic cirrhosis09.01.04.0010.001239%Not Available
Hepatic failure09.01.03.0020.001859%
Hepatic function abnormal09.01.02.001--Not Available
Hepatomegaly09.01.05.0010.001239%Not Available
Hypersensitivity10.01.03.0030.008426%
Hypotension24.06.03.0020.004337%
Hypothyroidism14.11.01.012; 05.02.03.0010.001239%
Hypoxia22.02.02.003--
Immobile26.01.01.002--Not Available
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site mass12.07.03.010; 08.02.03.009--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.0130.001239%Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Lenticular opacities06.06.01.003--Not Available
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.0040.001239%
Leukocytosis01.02.01.0020.002726%
Leukopenia01.02.02.001--Not Available
Liver disorder09.01.08.0010.001859%Not Available
Local reaction08.01.03.012--Not Available
Loss of consciousness17.02.04.0040.001239%Not Available
Lung infiltration22.01.02.0040.001239%Not Available
Maculopathy06.09.03.0070.003098%Not Available
Malaise08.01.01.0030.006691%
Miosis17.02.11.002; 06.05.03.0030.001239%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages